Editorial: Bladder cancer. How can we make a difference?
Soloway
Mark S
MS
D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods*; D003558:Cystoscopy / Q000379:methods*; D004326:Drinking / Q000502:physiology*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000503:physiopathology* / Q000517:prevention & control; D018714:Radiotherapy, Adjuvant; D016879:Salvage Therapy; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014563:Urodynamics / Q000502:physiology*